A three-dimensional (3D) medical animation of Ebola virus. Credit: Scientific Animations/Wikimedia.

Point-of-care diagnostics provider Chembio Diagnostics has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) to use its DPP Ebola Antigen System to detect the Ebola virus.

The EUA covers the use of the Ebola virus test, in combination with epidemiological risk factors, for a presumptive diagnosis of people who display signs and symptoms of the Ebola virus disease (EVD).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

DPP Ebola Antigen System comprises DPP Ebola Assay and a handheld, battery-operated Micro Reader. It is indicated for use with human capillary fingerstick whole blood, EDTA venous whole blood and EDTA plasma.

Based on the company’s DPP (Dual Path Platform) technology, the test is designed to identify viral antigens and delivers qualitative results in 15-20 minutes.

“We believe it will be a valuable tool to address the global threat posed by the Ebola virus, including the ongoing outbreak in the DRC.”

The system features a Micro Reader to minimise the risk of human error while interpreting the test results.

Chembio Diagnostics CEO John Sperzel said: “We are pleased to receive FDA emergency use authorisation for our DPP Ebola System as we believe it will be a valuable tool to address the global threat posed by the Ebola virus, including the ongoing outbreak in the DRC.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Our patented DPP technology continues to serve as a robust platform for the rapid detection of infectious diseases, and we hope to receive support and funding as we pursue additional regulatory approvals for our rapid Ebola test.”

The DPP technology is intended for rapid, point-of-care diagnostic testing. Chembio developed multiple products using this platform, including tests to detect tuberculosis, HIV and Zika.

The company’s portfolio also includes diagnostics for Syphilis and Chagas.

In April, Chembio formed an alliance with LumiraDx to develop point-of-care tests to diagnose a variety of infectious diseases.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact